Jun. 25, 2012, 9:29 AMShares of drug maker Shire (SHPGY, SHPGF.PK) -13% in London trading on news the FDA approved a generic version of its attention-deficit and hyperactivity drug Adderall XR. Watson Pharma's (WPI) newly acquired Actavis division obtained an abbreviated new-drug application for the generic. SHPGY -12.2%, WPU +1.9% premarket. | Comment!
Jun. 12, 2012, 9:07 AMBioMarin Pharmaceutical (BMRN) +4.8% premarket on rumors that Glaxo (GSK) is in advanced discussions toward a $5B buyout of BMRN. Last week, Shire (SHPGY, SHPGF.PK) also was said to be stalking the company. Glaxo is already engaged in a hostile $2.6B takeover bid for Human Genome Sciences. | Comment!
Jun. 22, 2011, 9:52 AM
SHPGF vs. ETF Alternatives
Other News & PR